CenterBook Partners LP Sells 43,178 Shares of GH Research PLC $GHRS

CenterBook Partners LP lowered its stake in GH Research PLC (NASDAQ:GHRS) by 62.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 26,258 shares of the company’s stock after selling 43,178 shares during the quarter. CenterBook Partners LP’s holdings in GH Research were worth $617,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its holdings in GH Research by 43.1% in the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after acquiring an additional 780 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in GH Research during the third quarter worth $82,000. China Universal Asset Management Co. Ltd. raised its position in GH Research by 30.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock worth $432,000 after acquiring an additional 4,106 shares during the period. Farther Finance Advisors LLC lifted its holdings in GH Research by 9,720.0% during the third quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock valued at $231,000 after purchasing an additional 9,720 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in GH Research during the second quarter valued at $495,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Price Performance

Shares of NASDAQ:GHRS opened at $19.25 on Thursday. The business’s 50 day moving average price is $22.67 and its 200-day moving average price is $21.62. The firm has a market capitalization of $1.32 billion, a PE ratio of -19.25 and a beta of 1.31. GH Research PLC has a 1 year low of $12.04 and a 1 year high of $31.44.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GHRS. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research report on Thursday, October 15th. Cantor Fitzgerald boosted their target price on shares of GH Research from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Zacks Research upgraded shares of GH Research from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. New Street Research set a $65.00 price target on shares of GH Research in a research note on Monday, August 10th. Finally, Wall Street Zen cut GH Research from a “hold” rating to a “sell” rating in a report on Saturday, October 24th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, GH Research presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.